Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | GFER | P55789 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23624939 | 0.84 | MAPT (0.55) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL12551054 | 0.80 | KDM4E (0.51) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL16447995 | 0.79 | MAPT (0.50) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL7043679 | 0.79 | MAPT (0.77) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL6151120 | 0.79 | MAPT (0.77) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL23347931 | 0.79 | MAPT (0.77) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL4563378 | 0.79 | KDM4E (0.59) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL24884606 | 0.79 | MAPT (0.64) | KDM4EMAPTALDH1A1GFERGAA | |
| SCHEMBL10001302 | 0.79 | KDM4E (0.59) | KDM4EMAPTALDH1A1GAAKMT2A | |
| SCHEMBL1235260 | 0.79 | KDM4E (0.59) | KDM4EMAPTALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115959651-B | Carbon point for quick and sensitive response to phosgene and application of carbon point in phosgene monitoring and removal | 郑州大学 | 2025-03-04 | — | — | CN | claimed |
| CN-115959651-A | Carbon dot for quickly and sensitively responding phosgene and phosgene monitoring and removing application thereof | 郑州大学 | 2023-04-14 | — | — | CN | claimed |
| US-20250214945-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-07-03 | — | — | US | disclosed |
| CN-115959651-B | Carbon point for quick and sensitive response to phosgene and application of carbon point in phosgene monitoring and removal | 郑州大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-115959651-B | Carbon point for quick and sensitive response to phosgene and application of carbon point in phosgene monitoring and removal | 郑州大学 | 2025-03-04 | — | — | CN | disclosed |
| EP-4506346-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-02-12 | — | — | EP | disclosed |
| CN-118974041-A | Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof | 高丽大学校产学协力团 | 2024-11-15 | — | — | CN | disclosed |
| CN-113365984-B | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2024-10-15 | — | — | CN | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | KDM4E 685/4885MAPT 4829/4885ALDH1A1 765/4885 |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | KDM4E 2606/4885MAPT 1359/4885ALDH1A1 4453/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | KDM4E 1256/4885MAPT 4847/4885ALDH1A1 1259/4885 |
| US-20250214945-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | TTBK2, TUBB3, TUBB | KDM4E 2839/4885MAPT 157/4885ALDH1A1 3214/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | KDM4E 1120/4885MAPT 985/4885ALDH1A1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.